

Guide to

# Assessment Scales in Schizophrenia

3rd edition

Richard Keefe

**Guide to**

# Assessment Scales in Schizophrenia

3rd edition

**Richard Keefe**

# Guide to Assessment Scales in Schizophrenia

3rd edition

*Editor*

**Richard Keefe**

*Contributors*

**Jean Addington, George Awad, Anthony S David, Donald Goff, Philip D Harvey,  
Michael Kraus, Julie Kreyenbuhl, Jonathan C Lee, Stephen Marder, Joseph P McEvoy,  
Ashwin A Patkar, Mark Taylor, Joseph Ventura**

Published by Springer Healthcare Ltd, 236 Gray's Inn Road, London, WC1X 8HB, UK.

[www.springerhealthcare.com](http://www.springerhealthcare.com)

©2012 Springer Healthcare, a part of Springer Science+Business Media.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

ISBN 978-1-908517-52-4

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Tamsin Curtis

Designer: Joe Harvey

Artworker: Sissan Mollerfors

Production: Marina Maher

Printed in Great Britain by Latimer Trend & Company Ltd.

# Contents

Author biographies	v
Preface	xi
<b>1 Symptom rating scales in schizophrenia</b>	<b>1</b>
Positive symptom scales	2
Negative symptom scales	7
References	8
<b>2 Depression and suicidality</b>	<b>9</b>
Depression	9
Suicidality	12
References	14
<b>3 Cognition</b>	<b>15</b>
Paper–pencil batteries	16
Computerized batteries	18
Interview-based assessments	19
References	30
<b>4 Functional outcomes assessment scales</b>	<b>33</b>
Functional rating scales	35
Everyday functioning scales	36
Functional capacity measures	36
Conclusions	37
References	37
<b>5 Quality of life measurements in a person with schizophrenia</b>	<b>39</b>
Scales for measurement of quality of life in schizophrenia	39
Disease-specific quality of life scales	39
Generic quality of life scales	41
Purpose-specific quality of life scales	42
Important considerations when using scales	43
References	43

## IV CONTENTS

<b>6</b>	<b>Antipsychotic side-effect rating scales in schizophrenia</b>	<b>45</b>
	Antipsychotic adverse side effects	45
	Side-effect or adverse-effect rating scales for schizophrenia	45
	References	52
<b>7</b>	<b>Assessment scales for insight</b>	<b>55</b>
	Measuring insight	55
	References	63
<b>8</b>	<b>Assessing adherence to antipsychotic medications</b>	<b>65</b>
	Drug Attitude Inventory	66
	Medication Adherence Rating Scale	66
	Brief Evaluation of Medication Influences and Beliefs	67
	Brief Adherence Rating Scale	69
	References	70
<b>9</b>	<b>Clinical assessment scales in substance use disorders</b>	<b>73</b>
	Diagnostic instruments	73
	Screening instruments	74
	Withdrawal rating scales	76
	Validity and reliability issues in self-report scales	77
	References	77
<b>10</b>	<b>Medical comorbidities</b>	<b>79</b>
	Setting the baseline	80
	Starting new antipsychotic medications	80
	Health issues for women	80
	Health issues for men	83
	References	84

## Author biographies

### Editor

**Richard Keefe, PhD**, is Professor of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina. He received his BA from Princeton University and his PhD in clinical psychology from New York University. His research is primarily devoted to understanding cognitive dysfunction and its treatment in patients with schizophrenia and related disorders, including those at high risk for schizophrenia. Dr Keefe has had a leadership role in several large National Institute of Mental Health studies including the CATIE, MATRICS, TURNS, and TENETS projects. He has authored more than 160 peer-reviewed scientific papers and two books. He serves on the editorial boards of several journals, including *Schizophrenia Research*, *Schizophrenia Bulletin*, and *Innovations in Clinical Neuroscience*, and is Associate Editor of *Psychological Medicine*. He is President of the International Society for CNS Clinical Trials and Methodology for 2012–2014. He is the Founder and CEO of NeuroCog Trials, Inc. He is a Co-Principal Investigator and Director of the Neurocognitive Core for the Translational and Clinical Research Neuroscience project at the Institute of Mental Health in Singapore.

### Contributors

**Jean Addington, PhD**, is Professor of Psychiatry at the University of Calgary and holds the Alberta Centennial Mental Health Research Chair and the Novartis Chair for Schizophrenia Research. Professor Addington graduated from The University of Calgary, Alberta, Canada. She has authored and contributed to a broad range of international publications and books on schizophrenia and other psychotic disorders and was one of the developers of the Calgary Depression Scale for Schizophrenia. Professor Addington's research interests are in early detection and intervention in psychosis, specifically the examination of predictors of conversion to psychosis and the development of psychosocial interventions for those at clinical high risk of psychosis.

**George Awad, MBBCh, PhD, FRCP(C)**, is currently Professor Emeritus of Psychiatry at the University of Toronto and is on the faculty of the Institute of Medical Science in the School of Graduate Studies. He is also the Chief of the Department of Psychiatry at Humber River Regional Hospital, Toronto, Ontario. Dr Awad is the recipient of the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a past President of the Canadian College of Neuropsychopharmacology. Recently, he was awarded the College Medal for meritorious contributions in psychopharmacology research, teaching and services. Dr Awad was the Founding President of the International Society for CNS Clinical Trials and Methodology for three years. Dr Awad continues to be extensively involved in training, research, and lecturing nationally and internationally. Dr Awad has published extensively including a number of books, the most recent of which is *Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders*.

**Anthony S David, MD, MSc, FRCP, FRCPsych**, is a clinical psychiatrist and academic currently working at the Maudsley Hospital, and Institute of Psychiatry, King's College London. He graduated in medicine from Glasgow University and trained in neurology before entering psychiatry. He has been Professor of Cognitive Neuropsychiatry since 1996 and is editor of the *Journal of Cognitive Neuropsychiatry* and has authored and contributed to over 400 peer-reviewed scientific articles in the field of schizophrenia, neuropsychiatry, neuropsychology and brain imaging, and has published several books, including *Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders*. He has a long-standing interest in schizophrenia as well as neuropsychology and brain imaging.

**Donald Goff, MD**, is Director of the Schizophrenia Program at Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School in Boston. Dr Goff earned his medical degree at the UCLA School of Medicine, Los Angeles, California, and completed his internship in Internal Medicine at Cedars-Sinai Medical Center in Los Angeles and his residency in Psychiatry at Massachusetts General Hospital in Boston, Massachusetts. His research fellowship in psychopharmacology was completed at Tufts-New England Medical Center in Boston. Dr Goff has published over 200 articles concerning schizophrenia and related topics. He is director of a clinical research program of 12 investigators integrating pharmacology, cognitive behavioral therapy, neuroimaging, and genetics to enhance understanding of the pathophysiology of schizophrenia and to develop new treatments. Dr Goff is the recipient of the Kempf Award for Mentorship in Biological Psychiatry from the American Psychiatric Association, the Wayne Fenton, MD, Award for Exceptional Clinical Care, and the Stanley Dean Award for Research in Schizophrenia from the American College of Psychiatrists.

**Philip D Harvey, PhD**, is Professor of Psychiatry at the University of Miami Miller School of Medicine. He is the author of over 800 scientific papers and abstracts and he has written over 50 book chapters. His work has been cited more than 500 times per year for the past decade, with over 1500 citations of his work in 2010. He has given more than 1800 presentations at scientific conferences and medical education events. He has edited five and written four books on topics of psychological assessment, schizophrenia, and aging. He has received a number of awards and is a member of the American Psychological Association, the American College of Neuropsychopharmacology (Fellow), the International College of Neuropsychopharmacology (Fellow), the Society for Research in Psychopathology (Founding Member), the Society for Biological Psychiatry, International Neuropsychological Society, the Schizophrenia International Research Society (Founding Director), and the International Society for Clinical Trials and Methodology (Founding Member). His research has focused on cognition and functioning and he has written extensively on aging in schizophrenia, functional impairments in severe mental illness, the cognitive effects of typical and atypical antipsychotics, as well as studying the effects of cognitive enhancing agents in various conditions, including schizophrenia, dementia, affective disorders, and traumatic brain injury.

**Michael S Kraus, MA**, is an Associate in Research in the Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, North Carolina. He graduated from Grinnell



College, Iowa, before attending the Yale Neurobiology graduate program at Yale University, New Haven, Connecticut. Michael Kraus has authored and contributed to several international publications. His principal research interests include cognitive deficits in schizophrenia and auditory and emotional processing deficits in schizophrenia.

**Julie Kreyenbuhl, PharmD, PhD**, is a research investigator with the US Department of Veterans Affairs Capitol Healthcare Network Mental Illness Research, Education, and Clinical Center and a member of the faculty at the University of Maryland School of Medicine, Department of Psychiatry, Division of Services Research. She completed her clinical pharmacy training at Mercer University College of Pharmacy and Health Sciences in Atlanta, Georgia, in 1993 and received a PhD in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy in Baltimore, Maryland, in 1999. She completed a post-doctoral fellowship at the Maryland Psychiatric Research Center in Baltimore, Maryland, in 2000. Dr Kreyenbuhl has authored or co-authored over 50 publications in peer-reviewed journals and has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia. Her current research focuses on testing the effectiveness of computer technology-based interventions for individuals with serious mental illnesses in the areas of enhancing adherence to and providing education about the medication side effects of antipsychotic medications.

**Jonathan C Lee, MD**, is the Associate Medical Director of the Farley Center at Williamsburg Place in Virginia. He is a graduate of the Massachusetts Institute of Technology, and the University of Virginia School of Medicine. In 2010 he completed a combined residency in internal medicine and psychiatry at Duke University Medical Center in Durham, North Carolina, serving as Chief Resident of Medicine and Psychiatry from 2009 to 2010. He is Board Certified with the American Board of Internal Medicine and is Board Eligible with the American Board of Psychiatry and Neurology as well as the American Board of Addiction Medicine. Dr Lee is a member of the Association of Medicine and Psychiatry, American College of Physicians, American Psychiatric Association, American Academy of Addiction Psychiatry, and American Society of Addiction Medicine. He has authored and contributed to literature in psychosomatic medicine and addiction medicine. He has conducted clinical research in collaboration with the Duke Addictions Program in Durham, North Carolina.

**Stephen R Marder, MD**, is Professor and Director of the Section on Psychosis at the UCLA Semel Institute for Neuroscience and Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs. He graduated from the University of Pennsylvania and received his medical degree from the State University of New York, Buffalo. After an internship at Denver General Hospital he completed a residency at the University of Southern California. He was a Clinical Associate in the Biological Psychiatry Branch at the National Institute of Mental Health from 1975–1977, then in 1977 he joined the staff at the Brentwood VA Medical Center and the faculty at UCLA. Dr Marder's research has focused on the drug treatment